Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT06485895
Recruiting Not applicable

Clinical Evaluation of an IGRA Test for the Diagnosis of Active and Latent Tuberculosis

NCT06485895 · tracked via the Priya Life Science France tracker
Sponsor
Assistance Publique Hopitaux De Marseille
Phase
Not applicable
Started
2024-07-30
Last updated
2024-08-01

Condition(s) studied

TUBERCULOSIS

Investigational drug(s) / intervention(s)

test IGRATEST QUATIFERON TB Gold Plus

test IGRA: BLOOD SAMPLES

TEST QUATIFERON TB Gold Plus: BLOOD SAMPLES

Study summary

Methodology This is a single-center study carried out as part of routine patient care.

The aim of the study is to determine the performance of the 2nd generation TB-IGRA test in the diagnosis of tuberculosis.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Individual at least 18 years of age * Patient presenting for treatment of tuberculosis disease * Having undergone or benefiting from screening for tuberculosis using a medically prescribed reference IGRA test. * Informed patient who has not expressed opposition to participating in the study. French-speaking patient with unambiguous understanding of oral and written instructions. Exclusion Criteria: Persons in a period of exclusion from another study * Pregnant, parturient or breast-feeding women; * Person deprived of liberty by judicial or administrative decision

Primary outcome measure(s)

  • sensitivity of TB-IGRA 2nd generation test — 24 MONTHS
  • specificity of TB-IGRA 2nd generation test — 24 MONTHS

Trial sites (1)

FacilityCityRegionStatus
Assistance Publique Hopitaux de Marseille Marseille France Recruiting

More Assistance Publique Hopitaux De Marseille trials in France

Involving Family Stakeholders in the NICU: a New Perspective to Improve Quality of Life. PAREN Starting soon
Efficacy of Light Therapy in Treatment of Chronic Cluster Headache Recruiting
Micro Assays for HemATology Malignancies Antibody Treatment Starting soon
Predicting Reactions and Effects of Drugs Immunotherapy and Complications Through Oncosafety (PREDICTO Clinical Study) Starting soon
Improving the Quality of Anesthesia Induction by Reducing Preoperative Anxiety in the Operating Room Recruiting

Other trials for the same condition

Immunological Biomarkers in Tuberculosis Management Recruiting
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) Recruiting
Hospital and Extra-hospital Nursing Care for Tuberculosis Starting soon
MoMa Signature During Granulomatosis Recruiting
Prospective Cohort of People Starting Treatment for Tuberculosis Disease in France (FrenchTB) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06485895 on ClinicalTrials.gov ↗ ← All trials in France